Sugi Predict

Sugi Predict / Compounds / SCHEMBL4463046

SCHEMBL4463046

SCHEMBL4463046

CNS(=O)(=O)c1ccc(C2=NNC(=O)/C2=C2/C=Cc3ccccc3N2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ GAA P10253 2/20 0.36
▸ PIP4K2A P48426 1/20 0.35
▸ PIP4K2B P78356 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ G6PD P11413 1/20 0.35
▸ NR3C2 P08235 1/20 0.34
▸ DRD1 P21728 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ HPGD P15428 2/20 0.33
▸ KIF11 P52732 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA3 P07451 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463051 1.00 SMN1; SMN2 (0.36) SMN1; SMN2GAAPIP4K2APIP4K2BKMT2A
SCHEMBL4465969 0.85 PSIP1 (0.36) GAAKMT2AALDH1A1MAPTPTGS2
SCHEMBL4465966 0.85 PSIP1 (0.36) GAAKMT2AALDH1A1MAPTPTGS2
SCHEMBL4460358 0.83 MAPT (0.43) SMN1; SMN2GAAKMT2AMEN1ALDH1A1
SCHEMBL4460352 0.83 MAPT (0.43) SMN1; SMN2GAAKMT2AMEN1ALDH1A1
SCHEMBL4474579 0.78 BRD4 (0.38) GAAMAPT
SCHEMBL4474572 0.78 BRD4 (0.38) GAAMAPT
SCHEMBL4459243 0.74 HTR6 (0.36) POLBL3MBTL1
SCHEMBL4459250 0.74 HTR6 (0.36) POLBL3MBTL1
SCHEMBL4459200 0.72 MAPT (0.46) SMN1; SMN2GAAMAPTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 — — US claimed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 — — EP claimed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 — — WO claimed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 — — US claimed
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 — — US disclosed
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 — — US disclosed
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 — — US disclosed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 — — EP disclosed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 — — WO disclosed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041137-A1 Kinase inhibitors MAP3K19, MAP3K20, MAP3K1 SMN1; SMN2 4388/4885GAA 3059/4885PIP4K2A 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.